Brokers Offer Predictions for UNCY FY2030 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a research note issued to investors on Monday, January 26th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of $9.77 for the year. HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.20.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 2nd. Guggenheim reiterated a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.33.

Unicycive Therapeutics Stock Performance

Shares of UNCY stock opened at $7.02 on Tuesday. Unicycive Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $11.00. The company has a 50 day moving average price of $6.11 and a 200 day moving average price of $5.06. The stock has a market capitalization of $150.86 million, a P/E ratio of -1.78 and a beta of 1.85.

Institutional Investors Weigh In On Unicycive Therapeutics

Several institutional investors have recently modified their holdings of UNCY. Lazard Asset Management LLC purchased a new position in Unicycive Therapeutics in the second quarter valued at $55,000. JPMorgan Chase & Co. boosted its position in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at about $182,000. Squarepoint Ops LLC purchased a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at about $512,000. Finally, Vanguard Group Inc. raised its position in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after acquiring an additional 52,925 shares in the last quarter. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.